Resources in Action Hub
Learn how DiMe resources position our community to redefine healthcare and improve lives
DiMe’s Resources in Action Hub spotlights how leaders, innovators, and digital enthusiasts use DiMe’s work to advance the use of digital medicine to redefine healthcare and improve lives.
Browse our Hub to learn about the:
DiMe’s Impact by the Numbers
8 of the top 15 pharmaceutical companies (by revenue) have shared a case study on how a DiMe resource have helped them solve a problem
4 of the top 12 pharmaceutical companies (by revenue) have shared case studies on how they use The Playbook: Digital Clinical Measures Edition
Over 300 DiMe Project Collaborators from organizations across the industry have contributed to the development of DiMe resources
DiMe’s V3 Framework – and its extension, V3+ – has been accessed over 30,000 times and leveraged by over 130 teams, including NIH, FDA, and EMA.
Over 100 uses of DiMe-developed definitions, including the definitions of digital medicine and virtual first care (V1C).
Want to see more? View full infographic of DiMe’s Impact
Last updated August 14, 2024
DiMe Case Studies
DiMe’s case hub spotlights how teams drive impact using DiMe resources in their work. Browse the cases from leaders in the field below and to learn how you can start leveraging DiMe resources in action today.
“Applying technological advances to ADRD remains an underutilized resource. Patients, caregivers, clinicians, researchers cannot act on what they do not know. Having an ADRD resource that highlights how technology can advance science, treatment and care will bring to light the many opportunities that exist today to rapidly transform the pace in which we combat this disease.”
“The digital biomarker space in general is advancing very rapidly, which is great news for patients and researchers. As a researcher, l’ve had trouble in both finding CNS-relevant digital tools, and in determining how well developed and validated they are. Many companies that provide tools like this don’t share validation evidence in a single place – it’s often scattered across papers, posters, press releases, clinicaltrials.gov – or just not available online. I’ve done plenty of manual literature reviews over the years to aggregate this information, but it’s a very time-consuming process, and the output quickly goes out of date. The DiMe digital measurement products library provides a centralized, unified platform for this material, which will make digital biomarker selection much easier – hopefully leading to accelerated development of treatments for patients.”
“DiMe’s resources have been essential for advancing at-home sensor data capture and improving assessment methods to make clinical trials more efficient. DiMe’s standardized framework, including the V3 and V3+ validation tools, helps ensure accuracy and reliability in our work. This framework is a valuable resource for understanding and implementing digital health technologies. These efforts aim to reduce patient burden while delivering reliable evidence to support progress in ADRD research and care. The DiMe digital measurement products library provides a clear and practical tool for selecting digital biomarkers, helping to accelerate the development of new treatments for patients.”
“Monitors that allow stress tracking, symptom tracking, and other metrics give words to what many people feel, experience, and live with every day. This tool not only empowers someone living with the symptoms but validates them by making it tangible data that can inform medical decisions in real-time. Gone are the days of being told, “It’s just in your head,” when you can show how it feels to have anxiety, depression, insomnia, or other diagnoses and symptoms through the use of smart technology!”
“Open mHealth’s purpose is to standardize digital health measures for data exchange. Our work will profit from the report’s findings pertaining to the most meaningful aspects of health relevant to anxiety, depression and psychosis that can be measured using sensor-based digital health technologies (sDHTs) and what the measures are.
Based on the findings, we can direct our efforts towards modeling such measures and ensure that the resulting models (schemas) include data elements to fully capture those measures and the relevant contextual information.
This will ensure that when digitally measured data are used, they are as complete as possible for analysis and other uses, including interventions.”
“This report represents the next step in the two-year collaborative effort between DiMe, the UCLA Depression Grand Challenge, Wellcome, and other organizations laying the groundwork for establishing standards for the use of digital sensing in mental health research, diagnosis, and treatment. The UCLA Depression Grand Challenge is honored to participate in these collaborations that offer the promise to transform the field. We look forward to seeing how various stakeholders take the findings and recommendations in the report and apply them in terms of investment and practice.”
“As a transracial transnational adoptee with no family history, research that can provide even a fraction of insight to help bridge the giant gaps in my health history is critical not only for myself, but my child and her future children. While sensor-based digital technologies provide imperative data and convenience; it will also improve quality of life for folks like myself who navigate life with multiple mental health diagnoses.”
“Incorporating lived, experienced individuals’ voices into research that directly affects them is the kind of intentionality that can truly help people and change their lives. Expanding into different avenues of treatment options can help create more options for care.”
Anabella Aspiras, The White House, expresses her excitement about CancerX’s launch of navigation resources and its impact on the health system’s ability to provide scaled and sustainable patient navigation. These efforts are needed to ensure equitable access, adoption, and availability of high-quality navigation services.
Danielle Brown, Florida Cancer Specialist, elaborates on how CancerX’s navigation resources have helped to address and reduce barriers to care. She particularly praises the ROI tool that she was able to test, stating that it helped tell the story of what an organization needs and what the ROI can be.
Cate O’Reilly, Cancer Support Community, explains how CancerX’s Digitally Enabled Patient Navigation Blueprint can impact patient and healthcare outcomes, help providers identify and articulate needs, and provide on-demand patient support.
Steve Xu praises DiMe for thinking about how words and definitions matter in relation to scratch. To better understand what scratch means, knowing the many different ways to talk about it and having this specificity is important.
Steve Xu appreciates DiMe’s work on ontology, frameworks, and definitions because it directly leads to outcomes, measurements, and technologies. Those tools can be put in front of regulators, which leads to the correct levels of clinical validation and acceptance.
“The V3 Testing within the DATAcc Toolkit for Development… is where my team in our trying to bring precision health to everyone is building devices and tools that let us generate objective real-world evidence… this is why I love this framing.” – Kristin Size, Head of Study Devices, Verily
“Applying technological advances to ADRD remains an underutilized resource. Patients, caregivers, clinicians, researchers cannot act on what they do not know. Having an ADRD resource that highlights how technology can advance science, treatment and care will bring to light the many opportunities that exist today to rapidly transform the pace in which we combat this disease.”
“The digital biomarker space in general is advancing very rapidly, which is great news for patients and researchers. As a researcher, l’ve had trouble in both finding CNS-relevant digital tools, and in determining how well developed and validated they are. Many companies that provide tools like this don’t share validation evidence in a single place – it’s often scattered across papers, posters, press releases, clinicaltrials.gov – or just not available online. I’ve done plenty of manual literature reviews over the years to aggregate this information, but it’s a very time-consuming process, and the output quickly goes out of date. The DiMe digital measurement products library provides a centralized, unified platform for this material, which will make digital biomarker selection much easier – hopefully leading to accelerated development of treatments for patients.”
“DiMe’s resources have been essential for advancing at-home sensor data capture and improving assessment methods to make clinical trials more efficient. DiMe’s standardized framework, including the V3 and V3+ validation tools, helps ensure accuracy and reliability in our work. This framework is a valuable resource for understanding and implementing digital health technologies. These efforts aim to reduce patient burden while delivering reliable evidence to support progress in ADRD research and care. The DiMe digital measurement products library provides a clear and practical tool for selecting digital biomarkers, helping to accelerate the development of new treatments for patients.”
“Monitors that allow stress tracking, symptom tracking, and other metrics give words to what many people feel, experience, and live with every day. This tool not only empowers someone living with the symptoms but validates them by making it tangible data that can inform medical decisions in real-time. Gone are the days of being told, “It’s just in your head,” when you can show how it feels to have anxiety, depression, insomnia, or other diagnoses and symptoms through the use of smart technology!”
“Open mHealth’s purpose is to standardize digital health measures for data exchange. Our work will profit from the report’s findings pertaining to the most meaningful aspects of health relevant to anxiety, depression and psychosis that can be measured using sensor-based digital health technologies (sDHTs) and what the measures are.
Based on the findings, we can direct our efforts towards modeling such measures and ensure that the resulting models (schemas) include data elements to fully capture those measures and the relevant contextual information.
This will ensure that when digitally measured data are used, they are as complete as possible for analysis and other uses, including interventions.”
“This report represents the next step in the two-year collaborative effort between DiMe, the UCLA Depression Grand Challenge, Wellcome, and other organizations laying the groundwork for establishing standards for the use of digital sensing in mental health research, diagnosis, and treatment. The UCLA Depression Grand Challenge is honored to participate in these collaborations that offer the promise to transform the field. We look forward to seeing how various stakeholders take the findings and recommendations in the report and apply them in terms of investment and practice.”
“As a transracial transnational adoptee with no family history, research that can provide even a fraction of insight to help bridge the giant gaps in my health history is critical not only for myself, but my child and her future children. While sensor-based digital technologies provide imperative data and convenience; it will also improve quality of life for folks like myself who navigate life with multiple mental health diagnoses.”
“Incorporating lived, experienced individuals’ voices into research that directly affects them is the kind of intentionality that can truly help people and change their lives. Expanding into different avenues of treatment options can help create more options for care.”
Anabella Aspiras, The White House, expresses her excitement about CancerX’s launch of navigation resources and its impact on the health system’s ability to provide scaled and sustainable patient navigation. These efforts are needed to ensure equitable access, adoption, and availability of high-quality navigation services.
Danielle Brown, Florida Cancer Specialist, elaborates on how CancerX’s navigation resources have helped to address and reduce barriers to care. She particularly praises the ROI tool that she was able to test, stating that it helped tell the story of what an organization needs and what the ROI can be.
Cate O’Reilly, Cancer Support Community, explains how CancerX’s Digitally Enabled Patient Navigation Blueprint can impact patient and healthcare outcomes, help providers identify and articulate needs, and provide on-demand patient support.
Steve Xu praises DiMe for thinking about how words and definitions matter in relation to scratch. To better understand what scratch means, knowing the many different ways to talk about it and having this specificity is important.
Steve Xu appreciates DiMe’s work on ontology, frameworks, and definitions because it directly leads to outcomes, measurements, and technologies. Those tools can be put in front of regulators, which leads to the correct levels of clinical validation and acceptance.
“The V3 Testing within the DATAcc Toolkit for Development… is where my team in our trying to bring precision health to everyone is building devices and tools that let us generate objective real-world evidence… this is why I love this framing.” – Kristin Size, Head of Study Devices, Verily
